You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameParoxetine
Accession NumberDB00715
TypeSmall Molecule
GroupsApproved, Investigational
Description

Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.

Structure
Thumb
Synonyms
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
Paroxetina
Paroxetine
Paroxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Paroxetinetablet30 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Act Paroxetinetablet20 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Act Paroxetinetablet10 mgoralActavis Pharma Company2005-03-14Not applicableCanada
Auro-paroxetinetablet10 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetinetablet30 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetinetablet20 mgoralAuro Pharma Inc2012-07-24Not applicableCanada
Bio-paroxetinetablet20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetinetablet10 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-paroxetinetablet30 mgoralBiomed PharmaNot applicableNot applicableCanada
Brisdellecapsule7.5 mg/1oralNOVEN THERAPEUTICS, LLC2013-06-28Not applicableUs
Dom-paroxetinetablet30 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetinetablet20 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Dom-paroxetinetablet40 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-paroxetinetablet10 mgoralDominion Pharmacal2004-02-06Not applicableCanada
Ipg-paroxetinetablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetinetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-paroxetinetablet30 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-paroxetinetablet30 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-paroxetinetablet20 mgoralJamp Pharma Corporation2011-10-24Not applicableCanada
Jamp-paroxetinetablet10 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Mar-paroxetinetablet30 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetinetablet10 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mar-paroxetinetablet20 mgoralMarcan Pharmaceuticals Inc2014-06-24Not applicableCanada
Mint-paroxetinetablet20 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetinetablet10 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mint-paroxetinetablet30 mgoralMint Pharmaceuticals Inc2014-03-17Not applicableCanada
Mylan-paroxetinetablet30 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetinetablet20 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Mylan-paroxetinetablet10 mgoralMylan Pharmaceuticals Ulc2003-10-08Not applicableCanada
Ntp-paroxetinetablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetinetablet30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-paroxetinetablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-paroxetinetablet30 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetinetablet20 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-paroxetinetablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Paroxetinetablet20 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet30 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet20 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet30 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet10 mgoralSivem Pharmaceuticals Ulc2012-06-26Not applicableCanada
Paroxetinetablet20 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet30 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet10 mgoralSanis Health Inc2009-10-22Not applicableCanada
Paroxetinetablet30 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetinetablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet20 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetinetablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Paroxetinetablet30 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Paroxetinetablet10 mgoralMeliapharm Inc2004-04-062014-06-25Canada
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralApotex Corp2010-09-13Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralbryant ranch prepack2010-09-13Not applicableUs
Paroxetine-10tablet10 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-20tablet20 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paroxetine-30tablet30 mgoralPro Doc Limitee2004-03-19Not applicableCanada
Paxiltablet, film coated40 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated30 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated20 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated30 mg/1oralPhysicians Total Care, Inc.1996-07-10Not applicableUs
Paxiltablet, film coated10 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxiltablet, film coated20 mg/1oralPhysicians Total Care, Inc.2006-09-18Not applicableUs
Paxilsuspension10 mg/5mLoralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralSTAT Rx USA LLC2002-04-09Not applicableUs
Paxil CRtablet, film coated, extended release25 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet (extended-release)37.5 mgoralGlaxosmithkline IncNot applicableNot applicableCanada
Paxil CRtablet (extended-release)25 mgoralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRtablet (extended-release)12.5 mgoralGlaxosmithkline Inc2004-01-05Not applicableCanada
Paxil CRtablet, film coated, extended release25 mg/1oralRebel Distributors Corp2002-04-09Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil CRtablet, film coated, extended release12.5 mg/1oralRebel Distributors Corp2002-04-09Not applicableUs
Paxil CRtablet, film coated, extended release37.5 mg/1oralApotex Corp2011-01-01Not applicableUs
Paxil Tab 10mgtablet10 mgoralGlaxosmithkline Inc1997-01-31Not applicableCanada
Paxil Tab 20mgtablet20 mgoralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxil Tab 30mgtablet30 mgoralGlaxosmithkline Inc1993-12-31Not applicableCanada
Paxilcr CRtablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2005-07-06Not applicableUs
Paxilcr CRtablet, film coated, extended release25 mg/1oralPhysicians Total Care, Inc.2003-05-16Not applicableUs
Paxilcr CRtablet, film coated, extended release37.5 mg/1oralPhysicians Total Care, Inc.2005-07-21Not applicableUs
Pexevatablet, film coated10 mg/1oralREMEDYREPACK INC.2016-02-23Not applicableUs
Pexevatablet, film coated40 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated30 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated20 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
Pexevatablet, film coated10 mg/1oralNOVEN THERAPEUTICS, LLC2003-07-03Not applicableUs
PMS-paroxetinetablet40 mgoralPharmascience Inc2007-05-03Not applicableCanada
PMS-paroxetinetablet30 mgoralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetinetablet20 mgoralPharmascience Inc2003-10-29Not applicableCanada
PMS-paroxetinetablet10 mgoralPharmascience Inc2003-10-29Not applicableCanada
Priva-paroxetinetablet30 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetinetablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-paroxetinetablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Q-paroxetinetablet10 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetinetablet30 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Q-paroxetinetablet20 mgoralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ratio-paroxetinetablet30 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetinetablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Ratio-paroxetinetablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-10-092014-09-19Canada
Riva-paroxetinetablet30 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetinetablet20 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Riva-paroxetinetablet10 mgoralLaboratoire Riva Inc2004-02-16Not applicableCanada
Sandoz Paroxetinetablet10 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetinetablet30 mgoralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz Paroxetinetablet20 mgoralSandoz Canada Incorporated2004-09-212012-02-20Canada
Sandoz Paroxetinetablet30 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetinetablet20 mgoralSandoz Canada Incorporated2007-07-27Not applicableCanada
Sandoz Paroxetine Tabletstablet30 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine Tabletstablet20 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Sandoz Paroxetine Tabletstablet10 mgoralSandoz Canada Incorporated2014-10-31Not applicableCanada
Teva-paroxetinetablet20 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetinetablet10 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Teva-paroxetinetablet30 mgoralTeva Canada Limited2004-01-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paroxetinetablet30 mgoralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetinetablet20 mgoralApotex Inc2003-10-24Not applicableCanada
Apo-paroxetinetablet10 mgoralApotex Inc2003-10-24Not applicableCanada
Paroxetinetablet, film coated40 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2010-06-07Not applicableUs
Paroxetinetablet, film coated30 mg/1oralDIRECT RX2015-01-01Not applicableUs
Paroxetinetablet, film coated40 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-10-31Not applicableUs
Paroxetinetablet30 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated40 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2005-11-07Not applicableUs
Paroxetinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralbryant ranch prepack2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-03-11Not applicableUs
Paroxetinetablet10 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPhysicians Total Care, Inc.2008-10-15Not applicableUs
Paroxetinetablet, film coated30 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet10 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated40 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated30 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2010-06-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Paroxetinetablet, film coated40 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated40 mg/1oralPhysicians Total Care, Inc.2009-02-18Not applicableUs
Paroxetinetablet, film coated20 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated40 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2004-02-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralProficient Rx LP2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated40 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralTYA Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated30 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2011-08-16Not applicableUs
Paroxetinetablet, film coated20 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralApotheca Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2004-02-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralContract Pharmacy Services Pa2010-08-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralSTAT Rx USA LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralClinical Solutions Wholesale2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-06-02Not applicableUs
Paroxetinetablet, film coated40 mg/1oralZydus Pharmaceuticals (USA) Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
Paroxetinetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Paroxetinetablet, film coated30 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated20 mg/1oralTYA Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-06-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralCardinal Health2011-05-19Not applicableUs
Paroxetinetablet, film coated10 mg/1oralGreenstone LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated40 mg/1oralDIRECT RX2016-02-29Not applicableUs
Paroxetinetablet, film coated40 mg/1oralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMed Vantx, Inc.2005-10-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSTAT Rx USA LLC2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMylan Institutional Inc.2005-12-26Not applicableUs
Paroxetinetablet, film coated20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet40 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2015-05-20Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated20 mg/1oralRebel Distributors Corp2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralH.J. Harkins Company, Inc.2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2005-11-02Not applicableUs
Paroxetinetablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralbryant ranch prepack2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralSolco Healthcare US, LLC2014-11-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2014-04-14Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2011-01-14Not applicableUs
Paroxetinetablet, film coated40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated10 mg/1oralAurobindo Pharma Limited2007-07-25Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMc Kesson Contract Packaging2011-09-16Not applicableUs
Paroxetinetablet, film coated20 mg/1oralBlenheim Pharmacal, Inc.2014-02-06Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2004-08-17Not applicableUs
Paroxetinetablet, film coated40 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet30 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated40 mg/1oralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated40 mg/1oralPd Rx Pharmaceuticals, Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated10 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Paroxetinetablet10 mg/1oralREMEDYREPACK INC.2011-04-18Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2007-04-132016-02-25Us
Paroxetinetablet, film coated20 mg/1oralbryant ranch prepack2007-04-13Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2008-03-24Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPd Rx Pharmaceuticals, Inc.2013-02-04Not applicableUs
Paroxetinetablet, film coated20 mg/1oralREMEDYREPACK INC.2013-12-05Not applicableUs
Paroxetinetablet20 mg/1oralInternational Laboratories, Inc.2007-12-11Not applicableUs
Paroxetinetablet, film coated10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated20 mg/1oralProficient Rx LP2009-12-03Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2007-07-25Not applicableUs
Paroxetinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated20 mg/1oralTeva Pharmaceuticals USA Inc2005-10-03Not applicableUs
Paroxetinetablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Paroxetinetablet, film coated10 mg/1oralGolden State Medical Supply, Inc.2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralbryant ranch prepack2003-09-08Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Paroxetinetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-03-24Not applicableUs
Paroxetinetablet, film coated40 mg/1oralREMEDYREPACK INC.2014-04-10Not applicableUs
Paroxetinetablet, film coated20 mg/1oralCardinal Health2011-05-19Not applicableUs
Paroxetinetablet, film coated30 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-11-20Not applicableUs
Paroxetinetablet, film coated20 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2007-04-13Not applicableUs
Paroxetinetablet, film coated20 mg/1oralPreferred Pharmaceuticals, Inc.2012-12-20Not applicableUs
Paroxetinetablet, film coated40 mg/1oralMajor Pharmaceuticals2010-06-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2004-04-07Not applicableUs
Paroxetinetablet, film coated10 mg/1oralApotex Corp.2003-09-08Not applicableUs
Paroxetinetablet, film coated30 mg/1oralCadila Healthcare Limited2007-04-13Not applicableUs
Paroxetinetablet, film coated30 mg/1oralMajor Pharmaceuticals2003-09-08Not applicableUs
Paroxetinetablet, film coated30 mg/1oralAurolife Pharma LLC2009-12-03Not applicableUs
Paroxetinetablet, film coated20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-11-08Not applicableUs
Paroxetinetablet, film coated40 mg/1oralLucid Pharma Llc2007-07-25Not applicableUs
Paroxetinetablet20 mg/1oralSun Pharmaceutical Industries, Inc.2007-06-29Not applicableUs
Paroxetinetablet, film coated20 mg/1oralSt. Mary's Medical Park Pharmacy2015-06-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralAmerican Health Packaging2011-05-19Not applicableUs
Paroxetinetablet, film coated40 mg/1oralAv Pak2016-03-11Not applicableUs
Paroxetinetablet, film coated20 mg/1oralUnit Dose Services2007-04-13Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-03-29Not applicableUs
Paroxetine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-11-03Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release37.5 mg/1oralMylan Pharmaceuticals Inc.2011-05-05Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralPhysicians Total Care, Inc.2008-05-23Not applicableUs
Paroxetine Hydrochloridetablet20 mg/1oralREMEDYREPACK INC.2011-07-11Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-06-17Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralPhysicians Total Care, Inc.2010-10-25Not applicableUs
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oralMylan Pharmaceuticals Inc.2008-05-14Not applicableUs
Paroxetine Hydrochloridetablet30 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs
Paroxetine Hydrochloridetablet40 mg/1oralREMEDYREPACK INC.2011-06-07Not applicableUs
Paroxetine Hydrochloride Anhydroustablet, film coated20 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AropaxNot Available
PAXILCRNot Available
SereupinNot Available
SeroxatNot Available
Seroxat CRNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Paroxetine hydrochloride
Thumb
  • InChI Key: GELRVIPPMNMYGS-RVXRQPKJSA-N
  • Monoisotopic Mass: 365.119399455
  • Average Mass: 365.826
DBSALT000132
Paroxetine hydrochloride hemihydrate
ThumbNot applicableDBSALT001742
Paroxetine mesylate
Thumb
  • InChI Key: SHIJTGJXUHTGGZ-RVXRQPKJSA-N
  • Monoisotopic Mass: 425.1308364
  • Average Mass: 425.471
DBSALT000133
Categories
UNII41VRH5220H
CAS number61869-08-7
WeightAverage: 329.3654
Monoisotopic: 329.142721716
Chemical FormulaC19H20FNO3
InChI KeyInChIKey=AHOUBRCZNHFOSL-YOEHRIQHSA-N
InChI
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
IUPAC Name
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
SMILES
FC1=CC=C(C=C1)[C@@H]1CCNC[[email protected]]1COC1=CC2=C(OCO2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Benzodioxole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationLabeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
PharmacodynamicsParoxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. In human platelets, paroxetine blocks the uptake of serotonin. It has weak effects on norepinephrine and dopamine neuronal reuptake. In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.
Mechanism of actionParoxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.
Related Articles
AbsorptionParoxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.
Volume of distribution

3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.

Protein binding~ 95% bound to plasma proteins.
Metabolism

Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy.

Route of eliminationApproximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound.
Half life21-24 hours
ClearanceNot Available
ToxicityLD50=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableC AlleleC Allele potentially associated with discontinuation syndrome in patients treated for anxiety or depression.20075642
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9869
Caco-2 permeable+0.5195
P-glycoprotein substrateSubstrate0.6555
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.6771
Renal organic cation transporterInhibitor0.5222
CYP450 2C9 substrateNon-substrate0.9265
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6004
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.8298
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8649
Ames testNon AMES toxic0.6722
CarcinogenicityNon-carcinogens0.9046
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.8239 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5554
hERG inhibition (predictor II)Non-inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Mylan pharmaceuticals inc
  • Actavis elizabeth llc
  • Alphapharm pty ltd
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Noven therapeutics llc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral7.5 mg/1
Tabletoral10 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral40 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral40 mg/1
Suspensionoral10 mg/5mL
Tablet (extended-release)oral12.5 mg
Tablet (extended-release)oral25 mg
Tablet (extended-release)oral37.5 mg
Tablet, film coated, extended releaseoral12.5 mg/1
Tablet, film coated, extended releaseoral25 mg/1
Tabletoral10 mg
Tabletoral20 mg
Tabletoral30 mg
Tablet, film coated, extended releaseoral37.5 mg/1
Tabletoral40 mg
Prices
Unit descriptionCostUnit
Paxil 30 40 mg tablet Bottle138.39USD bottle
Paxil 30 30 mg tablet Bottle131.0USD bottle
Paxil 30 10 mg tablet Bottle121.87USD bottle
Pexeva 40 mg tablet6.29USD tablet
Pexeva 30 mg tablet6.11USD tablet
Pexeva 20 mg tablet5.84USD tablet
Pexeva 10 mg tablet5.6USD tablet
Paxil CR 37.5 mg 24 Hour tablet4.5USD tablet
Paxil 40 mg tablet4.44USD tablet
Paxil CR 25 mg 24 Hour tablet4.37USD tablet
Paxil cr 37.5 mg tablet4.32USD tablet
Paxil 30 mg tablet4.2USD tablet
Paxil cr 25 mg tablet4.2USD tablet
Paxil CR 12.5 mg 24 Hour tablet4.18USD tablet
Paxil 20 mg tablet4.16USD tablet
PARoxetine HCl 37.5 mg 24 Hour tablet4.04USD tablet
Paxil cr 12.5 mg tablet4.02USD tablet
PARoxetine HCl 25 mg 24 Hour tablet3.93USD tablet
Paxil 10 mg tablet3.91USD tablet
PARoxetine HCl 12.5 mg 24 Hour tablet3.76USD tablet
Paroxetine hcl 40 mg tablet2.93USD tablet
Paroxetine hcl 30 mg tablet2.78USD tablet
Paroxetine hcl 20 mg tablet2.7USD tablet
Paroxetine hcl 10 mg tablet2.58USD tablet
Paxil 30 mg Tablet2.16USD tablet
Pms-Paroxetine 40 mg Tablet2.1USD tablet
Paxil 20 mg Tablet2.03USD tablet
Apo-Paroxetine 30 mg Tablet1.12USD tablet
Co Paroxetine 30 mg Tablet1.12USD tablet
Mylan-Paroxetine 30 mg Tablet1.12USD tablet
Novo-Paroxetine 30 mg Tablet1.12USD tablet
Phl-Paroxetine 30 mg Tablet1.12USD tablet
Pms-Paroxetine 30 mg Tablet1.12USD tablet
Ratio-Paroxetine 30 mg Tablet1.12USD tablet
Sandoz Paroxetine 30 mg Tablet1.12USD tablet
Apo-Paroxetine 20 mg Tablet1.05USD tablet
Co Paroxetine 20 mg Tablet1.05USD tablet
Mylan-Paroxetine 20 mg Tablet1.05USD tablet
Novo-Paroxetine 20 mg Tablet1.05USD tablet
Phl-Paroxetine 20 mg Tablet1.05USD tablet
Pms-Paroxetine 20 mg Tablet1.05USD tablet
Ratio-Paroxetine 20 mg Tablet1.05USD tablet
Sandoz Paroxetine 20 mg Tablet1.05USD tablet
Paxil 10 mg/5ml Suspension0.85USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2168829 No1997-12-162016-02-05Canada
CA2445678 No2009-11-242016-07-19Canada
US5789449 No1992-07-062009-07-06Us
US5811436 Yes1996-03-222016-03-22Us
US5872132 Yes1995-11-192015-11-19Us
US5874447 No1997-06-102017-06-10Us
US5900423 Yes1995-11-192015-11-19Us
US6063927 Yes1999-10-232019-10-23Us
US6080759 Yes1995-11-192015-11-19Us
US6121291 Yes1997-09-172017-09-17Us
US6133289 Yes1995-11-192015-11-19Us
US6172233 Yes1998-07-152018-07-15Us
US6548084 Yes1997-01-192017-01-19Us
US6703408 No2002-10-212022-10-21Us
US7229640 Yes1997-01-192017-01-19Us
US7598271 No2003-02-122023-02-12Us
US8658663 No2009-04-062029-04-06Us
US8946251 No2006-08-042026-08-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147-150 °C (mesylate salt) FDA label
water solubility>1 g/mL (mesylate salt) Not Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00853 mg/mLALOGPS
logP3.1ALOGPS
logP3.15ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.02 m3·mol-1ChemAxon
Polarizability34.48 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-8900000000-0a273deac3c7836cdc76View in MoNA
References
Synthesis Reference

Charles M. Zepp, Yun Gao, Donald L. Heefner, “Method of preparing optically pure precursors of paroxetine.” U.S. Patent US5258517, issued January, 1976.

US5258517
General References
  1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
  2. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6. [PubMed:10627793 ]
  3. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8. [PubMed:8834412 ]
  4. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81. [PubMed:9690692 ]
  5. Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001 Dec;21(6):556-60. [PubMed:11763001 ]
External Links
ATC CodesN06AB05
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (299 KB)
MSDSDownload (51.2 KB)
Interactions
Drug Interactions
Drug
AbciximabParoxetine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Paroxetine can be increased when it is combined with Abiraterone.
AcarboseParoxetine may increase the hypoglycemic activities of Acarbose.
AcenocoumarolParoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acepromazine.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Paroxetine.
AcetophenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acetophenazine.
Acetylsalicylic acidParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
AlbiglutideParoxetine may increase the hypoglycemic activities of Albiglutide.
AlfentanilAlfentanil may increase the serotonergic activities of Paroxetine.
AlogliptinParoxetine may increase the hypoglycemic activities of Alogliptin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.
AlteplaseParoxetine may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amoxapine.
AnistreplaseParoxetine may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Apixaban.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Paroxetine.
AripiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.
AsenapineParoxetine may increase the QTc-prolonging activities of Asenapine.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Paroxetine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paroxetine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.
BendroflumethiazideParoxetine may increase the activities of Bendroflumethiazide.
BenzquinamideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Benzquinamide.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Paroxetine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Paroxetine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.
BuspironeBuspirone may increase the serotonergic activities of Paroxetine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.
ButorphanolButorphanol may increase the serotonergic activities of Paroxetine.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Paroxetine.
CanagliflozinParoxetine may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.
CarbidopaThe risk or severity of adverse effects can be increased when Carbidopa is combined with Paroxetine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.
CarphenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Carphenazine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Paroxetine.
CelecoxibParoxetine may increase the antiplatelet activities of Celecoxib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlormezanone.
ChlorothiazideParoxetine may increase the activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paroxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paroxetine.
ChlorpropamideParoxetine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.
ChlorthalidoneParoxetine may increase the activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paroxetine.
CimetidineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.
CitalopramParoxetine may increase the QTc-prolonging activities of Citalopram.
Citric AcidParoxetine may increase the anticoagulant activities of Citric Acid.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Paroxetine.
ClofedanolThe risk or severity of adverse effects can be increased when Clofedanol is combined with Paroxetine.
ClomipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Paroxetine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.
ClozapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clozapine.
CobicistatThe serum concentration of Paroxetine can be increased when it is combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.
CollagenaseThe risk or severity of adverse effects can be increased when Paroxetine is combined with Collagenase.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.
CyproheptadineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateParoxetine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinParoxetine may increase the anticoagulant activities of Dalteparin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
DapagliflozinParoxetine may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.
DarunavirThe serum concentration of Paroxetine can be decreased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Paroxetine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Paroxetine is combined with Deoxycholic Acid.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.
DesipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.
DesmopressinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.
Dexchlorpheniramine maleateThe risk or severity of adverse effects can be increased when Dexchlorpheniramine maleate is combined with Paroxetine.
DextromethorphanParoxetine may increase the serotonergic activities of Dextromethorphan.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paroxetine.
DiclofenacParoxetine may increase the antiplatelet activities of Diclofenac.
DicoumarolParoxetine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.
DiflunisalParoxetine may increase the antiplatelet activities of Diflunisal.
DihydrocodeineParoxetine may increase the antiplatelet activities of Dihydrocodeine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paroxetine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paroxetine.
DisopyramideParoxetine may increase the hypoglycemic activities of Disopyramide.
DofetilideParoxetine may increase the QTc-prolonging activities of Dofetilide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Paroxetine.
DoxepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Paroxetine.
DulaglutideParoxetine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineDuloxetine may increase the serotonergic activities of Paroxetine.
Edetic AcidParoxetine may increase the anticoagulant activities of Edetic Acid.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Paroxetine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.
EmpagliflozinParoxetine may increase the hypoglycemic activities of Empagliflozin.
EnoxaparinParoxetine may increase the anticoagulant activities of Enoxaparin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.
ErythromycinParoxetine may increase the hypoglycemic activities of Erythromycin.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.
Ethyl biscoumacetateParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacParoxetine may increase the antiplatelet activities of Etodolac.
ExenatideParoxetine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
FencamfamineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fencamfamine.
FenoprofenParoxetine may increase the antiplatelet activities of Fenoprofen.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Paroxetine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.
FloctafenineParoxetine may increase the antiplatelet activities of Floctafenine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Paroxetine.
FluoxetineThe metabolism of Paroxetine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.
FlurbiprofenParoxetine may increase the antiplatelet activities of Flurbiprofen.
FluspirileneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Paroxetine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.
Fondaparinux sodiumParoxetine may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Paroxetine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Paroxetine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paroxetine.
GliclazideParoxetine may increase the hypoglycemic activities of Gliclazide.
GlimepirideParoxetine may increase the hypoglycemic activities of Glimepiride.
GlipizideParoxetine may increase the hypoglycemic activities of Glipizide.
GlucosamineGlucosamine may increase the antiplatelet activities of Paroxetine.
GlyburideParoxetine may increase the hypoglycemic activities of Glyburide.
GoserelinParoxetine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Paroxetine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
HeparinParoxetine may increase the anticoagulant activities of Heparin.
HydrochlorothiazideParoxetine may increase the activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.
HydromorphoneHydromorphone may increase the serotonergic activities of Paroxetine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Paroxetine.
IbuprofenParoxetine may increase the antiplatelet activities of Ibuprofen.
IcosapentParoxetine may increase the antiplatelet activities of Icosapent.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.
ImipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.
IndapamideParoxetine may increase the activities of Indapamide.
IndomethacinParoxetine may increase the antiplatelet activities of Indomethacin.
Insulin AspartParoxetine may increase the hypoglycemic activities of Insulin Aspart.
Insulin DegludecParoxetine may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirParoxetine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineParoxetine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineParoxetine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanParoxetine may increase the hypoglycemic activities of Insulin Regular.
Insulin LisproParoxetine may increase the hypoglycemic activities of Insulin Lispro.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine.
Ioflupane I 123Paroxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Paroxetine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paroxetine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.
KetoprofenParoxetine may increase the antiplatelet activities of Ketoprofen.
KetorolacParoxetine may increase the antiplatelet activities of Ketorolac.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Paroxetine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.
LanreotideParoxetine may increase the hypoglycemic activities of Lanreotide.
LeuprolideParoxetine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Paroxetine.
LevorphanolLevorphanol may increase the serotonergic activities of Paroxetine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.
LimaprostLimaprost may increase the antiplatelet activities of Paroxetine.
LinezolidLinezolid may increase the serotonergic activities of Paroxetine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Paroxetine.
LiraglutideParoxetine may increase the hypoglycemic activities of Liraglutide.
LithiumLithium may increase the serotonergic activities of Paroxetine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Paroxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
MecaserminParoxetine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.
Mefenamic acidParoxetine may increase the antiplatelet activities of Mefenamic acid.
MeloxicamParoxetine may increase the antiplatelet activities of Meloxicam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Paroxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.
MetforminParoxetine may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Paroxetine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Paroxetine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
MethyclothiazideParoxetine may increase the activities of Methyclothiazide.
Methylene blueParoxetine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.
MetolazoneParoxetine may increase the activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Paroxetine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paroxetine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Paroxetine.
MiglitolParoxetine may increase the hypoglycemic activities of Miglitol.
MoclobemideMoclobemide may increase the serotonergic activities of Paroxetine.
MolindoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Paroxetine.
NabumetoneParoxetine may increase the antiplatelet activities of Nabumetone.
NadololParoxetine may increase the activities of Nadolol.
NalbuphineNalbuphine may increase the serotonergic activities of Paroxetine.
NaproxenParoxetine may increase the antiplatelet activities of Naproxen.
NateglinideParoxetine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.
NefazodoneParoxetine may increase the serotonergic activities of Nefazodone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Paroxetine is combined with Obinutuzumab.
OctreotideParoxetine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paroxetine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Paroxetine.
OndansetronThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ondansetron.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.
OxaprozinParoxetine may increase the antiplatelet activities of Oxaprozin.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.
OxycodoneOxycodone may increase the serotonergic activities of Paroxetine.
OxymorphoneOxymorphone may increase the serotonergic activities of Paroxetine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paroxetine.
PanobinostatThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine.
PasireotideParoxetine may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineParoxetine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Paroxetine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Paroxetine.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Paroxetine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paroxetine.
PhenelzinePhenelzine may increase the serotonergic activities of Paroxetine.
PhenindioneParoxetine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paroxetine.
PhenprocoumonParoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Paroxetine.
PimozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Paroxetine.
PioglitazoneParoxetine may increase the hypoglycemic activities of Pioglitazone.
PiperacetazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Piperacetazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Paroxetine.
PiroxicamParoxetine may increase the antiplatelet activities of Piroxicam.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.
PramlintideParoxetine may increase the hypoglycemic activities of Pramlintide.
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paroxetine.
ProcarbazineProcarbazine may increase the serotonergic activities of Paroxetine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Paroxetine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Paroxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paroxetine.
QuinineParoxetine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.
RasagilineRasagiline may increase the serotonergic activities of Paroxetine.
RemifentanilRemifentanil may increase the serotonergic activities of Paroxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Remoxipride.
RepaglinideParoxetine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
ReteplaseParoxetine may increase the anticoagulant activities of Reteplase.
RidogrelParoxetine may increase the anticoagulant activities of Ridogrel.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Paroxetine.
RitonavirThe metabolism of Paroxetine can be decreased when combined with Ritonavir.
RivaroxabanParoxetine may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneParoxetine may increase the hypoglycemic activities of Rosiglitazone.
SaxagliptinParoxetine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Paroxetine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.
SelegilineSelegiline may increase the serotonergic activities of Paroxetine.
SertindoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sertindole.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paroxetine.
SitagliptinParoxetine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Paroxetine.
StreptokinaseParoxetine may increase the anticoagulant activities of Streptokinase.
SufentanilSufentanil may increase the serotonergic activities of Paroxetine.
SulfadiazineParoxetine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleParoxetine may increase the hypoglycemic activities of Sulfisoxazole.
SulindacParoxetine may increase the antiplatelet activities of Sulindac.
SulodexideParoxetine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.
SunitinibParoxetine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Paroxetine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
TenecteplaseParoxetine may increase the anticoagulant activities of Tenecteplase.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.
Thyroid, porcineThe therapeutic efficacy of Thyroid extract can be decreased when used in combination with Paroxetine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.
Tiaprofenic acidParoxetine may increase the antiplatelet activities of Tiaprofenic acid.
TiclopidineThe metabolism of Paroxetine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Paroxetine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Paroxetine.
TolazamideParoxetine may increase the hypoglycemic activities of Tolazamide.
TolbutamideParoxetine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
TolmetinParoxetine may increase the antiplatelet activities of Tolmetin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.
TositumomabThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tositumomab.
TramadolParoxetine may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Paroxetine.
TrazodoneParoxetine may increase the serotonergic activities of Trazodone.
TreprostinilParoxetine may increase the anticoagulant activities of Treprostinil.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.
TrichlormethiazideParoxetine may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.
TriflupromazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Triflupromazine.
TrimethoprimParoxetine may increase the hypoglycemic activities of Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.
UrokinaseParoxetine may increase the anticoagulant activities of Urokinase.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.
Vitamin EVitamin E may increase the antiplatelet activities of Paroxetine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.
WarfarinParoxetine may increase the anticoagulant activities of Warfarin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paroxetine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paroxetine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paroxetine.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387 ]
  2. Preuss UW, Soyka M, Bahlmann M, Wenzel K, Behrens S, de Jonge S, Kruger M, Bondy B: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Psychiatry Res. 2000 Sep 25;96(1):51-61. [PubMed:10980326 ]
  3. Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR: The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem. 2000 Oct;75(4):1608-17. [PubMed:10987842 ]
  4. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924 ]
  5. Wihlback AC, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T: Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol. 2001 Sep;98(3):450-7. [PubMed:11530128 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Rubin RT: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 2000 Nov 1;48(9):954-6. [PubMed:11203183 ]
  2. Gilmor ML, Owens MJ, Nemeroff CB: Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10. [PubMed:12359676 ]
  3. Nemeroff CB, Owens MJ: Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. [PubMed:14566196 ]
  4. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Bixo M, Allard P, Backstrom T, Mjorndal T, Nyberg S, Spigset O, Sundstrom-Poromaa I: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. 2001 Aug;26(6):551-64. [PubMed:11403977 ]
  2. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001 Jan;158(1):78-85. [PubMed:11136637 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 29, 2016 03:07